Brought to you by 
Padlock Therapeutics gets $23mm through Series A to fund PAD enzyme research
08 Jan 2015
Executive Summary
Padlock Therapeutics Inc., a newly formed company developing autoimmune disease treatments, raised $23mm through its Series A round. Co-founder Atlas Venture led and was joined by Index Ventures, J&J Development Corp., and MS Ventures.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Padlock Therapeutics gets $23mm through Series A to fund PAD enzyme research
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice